{"id":53386,"date":"2023-01-27T18:02:32","date_gmt":"2023-01-27T17:02:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/"},"modified":"2023-01-27T18:02:32","modified_gmt":"2023-01-27T17:02:32","slug":"maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/","title":{"rendered":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux"},"content":{"rendered":"
\n

LYON, France–(BUSINESS WIRE)–$MAAT<\/a>–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nMaaT Pharma<\/a><\/b><\/span> <\/b>(EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM<\/sup> (MET) dedicated to improving survival outcomes for patients with cancer,<\/b> today announces the initiation of coverage of its stock by Kepler Cheuvreux.\n<\/p>\n

\nWith a research report named \u201cThe Microbiome revolution\u201d<\/i>, Kepler Cheuvreux <\/b>today initiates coverage of MaaT Pharma with a Buy recommendation.\n<\/p>\n

\nThis new coverage strengthens the visibility of MaaT Pharma\u2019s share among French and international institutional investors and is in addition to those already carried out by the brokerage firms KBC Securities, Kempen and Portzamparc\/Groupe BNP Paribas.\n<\/p>\n

\nAbout MaaT Pharma<\/b>\n<\/p>\n

\nMaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint\u00ae<\/sup>, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions.\n<\/p>\n

\nThe company\u2019s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.\n<\/p>\n

\nMaaT Pharma is listed on Euronext Paris (ticker: MAAT).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMaaT Pharma \u2013 Investor Relations<\/b>
Herv\u00e9 AFFAGARD
\n
Co-Founder and CEO
\n
Si\u00e2n CROUZET, COO\/ CFO
\n
+33 4 28 29 14 00
\n
invest@maat-pharma.com<\/a>\n<\/p>\n

\nMaaT Pharma \u2013 Media Relations<\/b>
Pauline RICHAUD
\n
Senior PR & Corporate Communications Manager
\n
+33 6 14 06 45 92
\n
media@maat-pharma.com<\/a>\n<\/p>\n

\nTrophic Communications \u2013 Corporate and Medical Communications<\/b>
Gretchen SCHWEITZER or Charlotte SPITZ
\n
+49 171 351 27 33
\n
maat@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News: MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named \u201cThe Microbiome revolution\u201d, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53386","6":"format-standard","7":"category-industry"},"yoast_head":"\nMaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News: MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named \u201cThe Microbiome revolution\u201d, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-27T17:02:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux\",\"datePublished\":\"2023-01-27T17:02:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/\"},\"wordCount\":329,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005247\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/\",\"name\":\"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005247\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"datePublished\":\"2023-01-27T17:02:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005247\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230127005247\\\/en\\\/729326\\\/21\\\/Nov_2018_new_version_MaaT_Pharma_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/","og_locale":"en_US","og_type":"article","og_title":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend","og_description":"LYON, France–(BUSINESS WIRE)–$MAAT–Regulatory News: MaaT Pharma (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces the initiation of coverage of its stock by Kepler Cheuvreux. With a research report named \u201cThe Microbiome revolution\u201d, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-27T17:02:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux","datePublished":"2023-01-27T17:02:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/"},"wordCount":329,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/","url":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/","name":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","datePublished":"2023-01-27T17:02:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230127005247\/en\/729326\/21\/Nov_2018_new_version_MaaT_Pharma_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/maat-pharma-announces-initiation-of-coverage-of-its-stock-by-kepler-cheuvreux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53386"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53386\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}